[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2112335T3 - Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3. - Google Patents

Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3.

Info

Publication number
ES2112335T3
ES2112335T3 ES92922246T ES92922246T ES2112335T3 ES 2112335 T3 ES2112335 T3 ES 2112335T3 ES 92922246 T ES92922246 T ES 92922246T ES 92922246 T ES92922246 T ES 92922246T ES 2112335 T3 ES2112335 T3 ES 2112335T3
Authority
ES
Spain
Prior art keywords
lfa
inhibitors
interaction
prophylactic
diseases caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922246T
Other languages
English (en)
Inventor
Barbara P Wallner
Kevin D Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
University of Michigan
Original Assignee
Biogen Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, University of Michigan filed Critical Biogen Inc
Application granted granted Critical
Publication of ES2112335T3 publication Critical patent/ES2112335T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN METODOS PARA UTILIZAR INHIBIDORES DE LA INTERACCION CD2/LFA-3 EN EL TRATAMIENTO DE CONDICIONES DE LA PIEL CARACTERIZADAS POR LA PRESENTACION DE UN ANTIGEN ANORMAL Y ACTIVACION CELULAR T EN LA DERMIS Y EPIDERMIS EN MAMIFEROS, INCLUIDOS HUMANOS. TALES CONDICIONES INCLUYEN SORIASIS, DAÑOS UV, DERMATITIS ATIPICA, LINFOMA CALULAR T CUTANEO, TAL COMO HONGOS MICOSIS, DERMATITIS DE CONTACTO IRRITANTE Y ALERGICA, PLANUS LICHEN, AREATA ALOPECICA, GANGRENOSUM PIODERMA, VITILIGO, PENFIGOIDE CICATRICIAL Y URTICARIA.
ES92922246T 1991-10-07 1992-10-06 Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3. Expired - Lifetime ES2112335T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77096991A 1991-10-07 1991-10-07
US86202292A 1992-04-02 1992-04-02
HK98105235A HK1006056A1 (en) 1991-10-07 1998-06-12 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

Publications (1)

Publication Number Publication Date
ES2112335T3 true ES2112335T3 (es) 1998-04-01

Family

ID=27269909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92922246T Expired - Lifetime ES2112335T3 (es) 1991-10-07 1992-10-06 Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3.

Country Status (10)

Country Link
EP (1) EP0607332B1 (es)
JP (3) JPH07502496A (es)
AT (1) ATE161190T1 (es)
AU (1) AU677772B2 (es)
CA (1) CA2120732C (es)
DE (1) DE69223638T2 (es)
ES (1) ES2112335T3 (es)
GR (1) GR3026135T3 (es)
HK (1) HK1006056A1 (es)
WO (1) WO1993006866A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120731C (en) * 1991-10-07 2008-08-19 Barbara P. Wallner Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5795572A (en) 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
ES2153895T3 (es) 1994-03-08 2001-03-16 Dana Farber Cancer Inst Inc Metodos para modular la insensibilidad de celulas t.
US6185457B1 (en) 1994-05-31 2001-02-06 Galvani, Ltd. Method and apparatus for electrically forcing cardiac output in an arrhythmia patient
WO1999022765A1 (en) * 1997-10-30 1999-05-14 Brigham And Women's Hospital Control of lymphocyte localization by leep-cam activity
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
WO1999064068A1 (en) 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
JP2004527477A (ja) * 2001-02-01 2004-09-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｄ２結合因子を用いた、皮膚障害を処置または予防するための方法
US7858095B2 (en) 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
WO2005115436A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
DK1773384T3 (en) 2004-06-01 2015-11-23 Us Agriculture GM swine influenza virus and uses thereof
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
US8483822B1 (en) 2009-07-02 2013-07-09 Galvani, Ltd. Adaptive medium voltage therapy for cardiac arrhythmias
EP3511013B1 (en) 2010-08-24 2022-09-07 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2012106514A2 (en) 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP4361634A3 (en) 2012-03-19 2024-06-05 Stemline Therapeutics, Inc. Methods for treating and monitoring the status of cancer
CA2911191C (en) 2012-05-16 2023-02-28 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
US8750990B1 (en) 2012-12-12 2014-06-10 Galvani, Ltd. Coordinated medium voltage therapy for improving effectiveness of defibrillation therapy
JP6524094B2 (ja) 2013-08-30 2019-06-05 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤
BR112017015789A2 (pt) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus da influenza suína bivalente

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT503648E (pt) * 1991-03-12 2000-10-31 Biogen Inc Dominio do antigenio 3 associado a funcao linfocitica de ligacao as cd2
WO1992016563A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Monoclonal antibodies recognizing lymphocyte function associated antigen-3
CA2120731C (en) * 1991-10-07 2008-08-19 Barbara P. Wallner Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein

Also Published As

Publication number Publication date
DE69223638D1 (de) 1998-01-29
AU2890892A (en) 1993-05-03
JP2003137810A (ja) 2003-05-14
JP2005015493A (ja) 2005-01-20
JPH07502496A (ja) 1995-03-16
WO1993006866A3 (en) 1993-08-05
GR3026135T3 (en) 1998-05-29
EP0607332A1 (en) 1994-07-27
ATE161190T1 (de) 1998-01-15
WO1993006866A2 (en) 1993-04-15
CA2120732C (en) 2008-09-16
CA2120732A1 (en) 1993-04-15
HK1006056A1 (en) 1999-02-05
EP0607332B1 (en) 1997-12-17
DE69223638T2 (de) 1998-05-20
AU677772B2 (en) 1997-05-08

Similar Documents

Publication Publication Date Title
ES2112335T3 (es) Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3.
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
BR9402201A (pt) Solução oftálmica e método para tratar o olho contra irritação e secura
NO881051D0 (no) Metoder for behandling av solskadet, human hud med retinoider.
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
ATE415974T1 (de) Immunmodulatorische verbindungen sowie deren verwendungsverfahren
FI943625A (fi) Menetelmiä tulehduksellisten ihotautien hoitamiseksi
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
ATE514772T1 (de) Multipotente erwachsene stammzellen und verfahren zu deren isolierung
BR9702100A (pt) Sistemas e métodos para acabamento em linha de produtos celulares sangueíneos como plaquetas coletadas para fins terapéuticos
ATE147258T1 (de) Haarnachbehandlungsmittel
JP2008503295A (ja) 電磁放射線の美容における使用
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
IT8622795A0 (it) Metodo per un efficace trattamento idratante della pelle, particolarmente per applicazione in campo cosmetico.
PT952772E (pt) Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
ATE260639T1 (de) Sialylzucker und ihre derivaten enthaltende topische zubereitungen
GB8928634D0 (en) Method of testing
BG101126A (en) The use of muramylpeptide compounds
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
ITRM950154A0 (it) Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per il trattamento topico della dermatite atopica e di altre malattie della pelle.
DE59002154D1 (de) Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid oder ethambutol als aktive wirkstoffe.
AR023199A1 (es) Solucion acuosa estable de em12, y procedimiento de preparacion de dicha solucion
DE69432749D1 (de) Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 607332

Country of ref document: ES